LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations - Yang, J CH; Schuler, M H; Yamamoto, N (J Clin Oncol, 2012)
abstr LBA7500